Lupin Limited · NSE:LUPIN
Lupin — Q3 FY2023 Earnings Presentation
18 slides from Lupin's earnings presentation, Feb 10, 2023
Slide 1: Exchange filing cover letter
February 10, 2023 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q3 FY23 Pursuant to Regulation 30(
Slide 2: –
–
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q3 FY23 Performance
Q3 FY23 Performance 3
Slide 5: Q3 FY23 Key Highlights
Q3 FY23 Key Highlights Continued focus on profitable growth by optimization of direct and indirect costs Key Metrics Business Performance INR in mn India North America 42,446 mn 15,213 mn US: $177 mn Revenue 3% YoY 11% QoQ 3.8% YoY 3.7% QoQ 5,506 mn Growth Markets EMEA EBITDA 13% 4,187 mn 3,802 mn M
Slide 6: Q3 FY23 Financial Snapshot
Q3 FY23 Financial Snapshot Continued focus on profitable growth by optimization of direct and indirect costs Segmental breakup Key Financials INR in mn Revenue (In INR mn and %) Q3 FY23 Q2 FY23 Q3 FY22 India, North 15,213, 36% America, 15,271, 36% Total, Sales 42,446 40,912 40,875 42,446, 100% EBITD
Slide 7: India: An ongoing story of sustained outperformance in Rx
India: An ongoing story of sustained outperformance in Rx Lupin has grown at par with the market ex-in- Gaining significant launch momentum with licensed portfolio (ex IL) multiple new introductions in the quarter Overall Non-IL 10.2% Lupin grew at par with 7.6% 7.5% market at 10% in Q3 4 in 2 in 2
Slide 8: India: Increasing footprint by adjacencies and new divisions
India: Increasing footprint by adjacencies and new divisions Building end to end healthcare ecosystem Leveraging leadership by adding 6 by adding adjacencies and digital connect new divisions Softovac continues to grow and stays market leader #2 rank #3 rank #3 rank Aptivate continues to grow Respir
Slide 9: North America: Investing to increase complex share
North America: Investing to increase complex share Leadership: Delivering ~6% New product sales driving Growing Respiratory TRx volume of the U.S. US growth ($ mn) portfolio 181 177 159 21.1% 43.4% 121 #3 #1 Albuterol Arfometerol in the US1 in 42 products2 market share market share Q4 FY22 Q1 FY23 Q
Slide 10: Other Markets: Consistently growing
Other Markets: Consistently growing Other Developed Markets: Germany and Emerging Markets: Steady growth Australia driving growth • Strongest Quarter for Germany: • BRL 70 mn sales in Q3 FY23 EUR 11.4 mn vs EUR 8.8 mn (YoY) (growth 43% YoY); OTC growth EU5 29.7% Vs market 27.6% by • Mens health, Nam
Slide 11: Key Financial Metrics: FY23 Quarterly Trend
Key Financial Metrics: FY23 Quarterly Trend R&D (INR mn) Capex (INR Mn) Net debt/ Equity 15.0% 1,800 7.0% 0.27 3,900 1,613 0.25 3,600 3,478 3,376 1,540 1,555 13.0% 6.0% 3,300 1,500 2,896 0.21 3,000 11.0% 5.0% 2,700 1,200 2,400 9.6% 9.0% 4.5% 4.0% 2,100 7.0% 900 8.3% 3.8% 1,800 3.7% 3.0% 6.8% 1,500 5
Slide 12: P&L Highlights- Q3 FY23
P&L Highlights- Q3 FY23 QoQ YoY Amount in INR mn Q3FY23 % of Sales Q2FY23 % of Sales Q3FY22 % of Sales Growth Growth Sales 42,446 100.0% 40,912 100.0% 3.7% 40,875 100.0% 3.8% Other operating income 776 1.8% 543 1.3% 42.9% 734 1.8% 5.7% Total revenue 43,222 101.8% 41,455 101.3% 4.3% 41,609 101.8% 3.9
Slide 13: Sustainability: YTD FY23 Updates
Sustainability: YTD FY23 Updates Committed to accountability and public disclosure of ESG initiatives and metrics • Lupin has made significant progress in FY23 as an organization and made investments to enhance its ESG journey • Maintaining momentum towards enhancing our ESG systems and processes Ag
Slide 14: Lupin at a Glance
LUPIN AT A GLANCE 13
Slide 15: Lupin Today
Lupin Today Global Presence Local Leadership Purposeful diversification (9MFY23) 10th 3rd 6th API 7% Largest Generic Largest in India Pharma India North company the US Market Rank (by sales1) 38% America (by prescriptions3) (by sales3) 32% $2.2 bn 4th 8th Annual sales in Largest Australia South Afri
Slide 16: Vision: A Pharmaceutical Company Focused on Delivering High Quality Medicines
Vision: A Pharmaceutical Company Focused on Delivering High Quality Medicines to Patients Around the World Global Other United India Developed Emerging API States Region Markets Markets Evolving portfolio and Global operational Delivering innovative Global reach and scale Meaningful scale pipeline i
Slide 17: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards ATD (Association of Talent Development) BEST Vinita Gupta, named among India’s 20 Most Influential Women in Award Healthcare by BW Healthcare World Three Awards at Business Leadership Award 2022 Rajendra Chunodkar
Slide 18: Thank you
Thank you REGISTERED OFFICE youtube.com/c/LupinGlobal twitter.com/LupinGlobal 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400 055. India, linkedin.com/company/lupin/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com facebook.com/LupinWorld/